VEA
TTPH

Virtus ETF Advisers’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Virtus ETF Advisers’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,546
Closed -$402K – 279
2018
Q1 		$402K Buy
6,546
+3,564
+120% +$313K 0.35% 113
2017
Q4 		$376K Buy
2,982
+732
+33% +$93.7K 0.47% 67
2017
Q3 		$308K Buy
2,250
+206
+10% +$27.6K 0.04% 130
2017
Q2 		$292K Buy
+2,044
New +$316K 0.04% 132
2016
Q2 		– Sell
-1,324
Closed -$123K – 158
2016
Q1 		$123K Buy
+1,324
New +$132K 0.17% 135

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtus ETF Advisers's TTPH Position: Q2 2018 in Review

Virtus ETF Advisers sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2018, closing a stake of 6,546 shares — an estimated $402K sold.

Virtus ETF Advisers first reported a position in TTPH in Q1 2016 and held it in 5 quarters. The position peaked at $402K in Q1 2018. 90 funds tracked by Wall St. Rank hold TTPH as of Q2 2018.

  • Virtus ETF Advisers reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Virtus ETF Advisers sold 6,546 Tetraphase Pharmaceuticals, Inc. shares in Q2 2018, an estimated $402K.
  • Virtus ETF Advisers first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2016 and held it in 5 quarters.
  • Virtus ETF Advisers's Tetraphase Pharmaceuticals, Inc. position peaked at $402K in Q1 2018.
  • 90 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2018.

Based on Virtus ETF Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.